Analytical LC-MS/MS method for ezetimibe and its application for pharmacokinetic study

Journal of Liquid Chromatography and Related Technologies

Volumn 35, Issue 1, 2012, Pages 141-152

  Bae, Jung Woo ^a   Choi, Chang Ik ^b   Park, Sang Hun ^b   Jang, Choon Gon ^b   Lee, Seok Yong ^b  

^a Keimyung University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

ezetimibe; HPLC; human plasma; LC MS MS; pharmacokinetics; tandem mass

Indexed keywords

EZETIMIBE; HPLC; HUMAN PLASMAS; LC-MS/MS; TANDEM MASS;

ACETONITRILE; CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; ETHERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN); SOLVENT EXTRACTION;

PHARMACOKINETICS;

4 HYDROXYCHALCONE; CHALCONE DERIVATIVE; EZETIMIBE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 84863150703     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826076.2011.597065     Document Type: Article

References (28)

1. Altmann, S. W.; Davis, H. R. Jr.; Zhu, L. J.; Yao, X.; Hoos, L. M.; Tetzloff, G.; Iyer, S. P.; Maguire, M.; Golovko, A.; Zeng, M.; Wang, L.; Murgolo, N.; Graziano, M. P. Niemann-Pick C1 Like 1 Protein is Critical for Intestinal Cholesterol Absorption. Science 2004, 303 (5661), 1201-1204. (Pubitemid 38233587)
2. Garcia-Calvo, M.; Lisnock, J.; Bull, H. G.; Hawes, B. E.; Burnett, D. A.; Braun, M. P.; Crona, J. H.; Davis, H. R. Jr.; Dean, D. C.; Detmers, P. A.; Graziano, M. P.; Hughes, M.; Macintyre, D. E.; Ogawa, A.; O'neill, K. A.; Iyer, S. P.; Shevell, D. E.; Smith, M. M.; Tang, Y. S.; Makarewicz, A. M.; Ujjainwalla, F.; Altmann, S. W.; Chapman, K. T.; Thornberry, N. A. The Target of Ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (23), 8132-8137. (Pubitemid 40800055)
3. Zetia® [Ezetimibe prescribing informations]. Merck=Schering-Plough Pharmaceuticals, USA, 2006.
4. van Heek, M.; Farley, C.; Compton, D. S.; Hoos, L.; Alton, K. B.; Sybertz, E. J.; Davis, H. R. Jr. Comparison of the Activity and Disposition of the Novel Cholesterol Absorption Inhibitor, SCH58235, and Its Glucuronide, SCH60663. Br. J. Pharmacol. 2000, 129 (8), 1748-1754. (Pubitemid 30219019)
5. Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J. E.; Zbaida, S. Identification of Human UDP-Glucuronosyl-Transferase Enzyme(s) Responsible for the Glucuronidation of Ezetimibe (Zetia). Drug. Metab. Dispos. 2004, 32 (3), 314-320. (Pubitemid 38263889)
6. Simard, C.; Turgeon, J. The Pharmacokinetics of Ezetimibe. Can. J. Clin. Pharmacol. 2003, 10 (Suppl. 1), 13A-20A.
7. Patrick, J. E.; Kosoglou, T.; Stauber, K. L.; Alton, K. B.; Maxwell, S. E.; Zhu, Y.; Statkevich, P.; Iannucci, R.; Chowdhury, S.; Affrime, M.; Cayen, M. N. Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects. Drug. Metab. Dispos. 2002, 30 (4), 430-437. (Pubitemid 34263828)
8. Sistla, R.; Tata, V. S.; Kashyap, Y. V.; Chandrasekar, D.; Diwan, P. V. Development and Validation of a Reversed-Phase HPLC Method for the Determination of Ezetimibe in Pharmaceutical Dosage Forms. J. Pharm. Biomed. Anal. 2005, 39 (3-4), 517-522. (Pubitemid 41196057)
9. Basha, S. J.; Naveed, S. A.; Tiwari, N. K.; Shashikumar, D.; Muzeeb, S.; Kumar, T. R.; Kumar, N. V.; Rao, N. P.; Srinivas, N.; Mullangi, R.; Srinivas, N. R. Concurrent Determination of Ezetimibe and Its Phase-I and II Metabolites by HPLC with UV Detection: Quantitative Application to Various in vitro Metabolic Stability Studies and for Qualitative Estimation in Bile. J. Chromatogr. B. 2007, 853 (1-2), 88-96. (Pubitemid 46891335)
10. Li, S.; Liu, G.; Jia, J.; Li, X.; Yu, C. Liquid Chromatography-Negative Ion Electrospray Tandem Mass Spectrometry Method for the Quantification of Ezetimibe in Human Plasma. J. Pharm. Biomed. Anal. 2006, 40 (4), 987-992. (Pubitemid 43257906)
11. Oswald, S.; Scheuch, E.; Cascorbi, I.; Siegmund, W. A LC-MS=MS Method to Quantify the Novel Cholesterol Lowering Drug Ezetimibe in Human Serum, Urine and Feces in Healthy Subjects Genotyped for SLCO1B1. J. Chromatogr. B. 2006, 830 (1), 143-150. (Pubitemid 41831400)
12. Lee, Y. J.; Kim, Y. G.; Lee, M. G.; Chung, S. J.; Lee, M. H.; Shim, C. K. Analysis of Bioequivalence Study Using a Log-transformed Model. Yakhakhoeji 2000, 44 (4), 308-314.
13. Kosoglous, T.; Statkevich, P.; Johnson-Levonas, A. O.; Paolini, J. F.; Bergman, A. J.; Alton, K. B. Ezetimibe: A Review of Its Metabolism, Pharmacokinetics and Drug Interactions. Clin. Pharmacokinet. 2005, 44 (5), 467-494. (Pubitemid 40733733)
14. Yamamoto, K.; Sato, H.; Fujiyama, Y.; Doida, Y.; Bamba, T. Contribution of Two Missense Mutations (G71 R and Y486D) of the Bilirubin UDP Glycosyltransferase (UGT1A1) Gene to Phenotypes of Gilbert's Syndrome and Crigler-Najjar Syndrome Type II. Biochim. Biophys. Acta. 1998, 1406 (3), 267-273. (Pubitemid 28269309)
15. Bosma, P. J.; Chowdhury, J. R.; Bakker, C.; Gantla, S.; de Boer, A.; Oostra, B. A.; Lindhout, D.; Tytgat, G. N.; Jansen, P. L.; Oude Elferink, R. P.; Chowdhury, N. R. The Genetic Basis of the Reduced Expression of Bilirubin UDP-glucuronosyltransferase 1 in Gilbert's Syndrome. N. Engl. J. Med. 1995, 333 (18), 1171-1175.
16. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R.; Burchell, B. Genetic Variation in Bilirubin UPD-glucuronosyltransferase Gene Promoter and Gilbert's Syndrome. Lancet. 1996, 347 (9001), 578-581. (Pubitemid 26070740)
17. Iyer, L.; King, C. D.; Whitingtone, P. F.; Green, D.; Roy, S. K.; Tephly, B. L.; Ratain, M. J. Genetic Predisposition to the Metabolism of Irinotecan (CPT-11). Role of Uridine Diphosphate Glucuronosyltransferase Isoform 1A1 in the Glucuronidation of Its Active Metabolite (SN-38) in Human Liver Microsomes. J. Clin. Invest. 1998, 101 (4), 847-854. (Pubitemid 28096082)
18. Iyer, L.; Hall, D.; Das, S.; Mortell, M. A.; Ramírez, J.; Kim, S.; Di Rienzo, A.; Ratain, M. J. Phenotype-Genotype Correlation of in vitro SN-38 (Active Metabolite of Irinotecan) and Bilirubin Glucuronidation in Human Liver Tissue with UGT1A1 Promoter Polymorphism. Clin. Pharmacol. Ther. 1999, 65 (5), 576-582. (Pubitemid 29237332)
19. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis. Cancer. Res. 2000, 60 (24), 6921-6926. (Pubitemid 32059164)
20. Guillemette, C.; Millikan, R. C.; Newman, B.; Housman, D. E. Genetic Polymorphisms in Uridine Diphospho-Glucuronosyltransferase 1A1 and Association with Breast Cancer Among African Americans. Cancer. Res. 2000, 60 (4), 950-956. (Pubitemid 30129531)
21. Maruo, Y.; Sato, H.; Bamba, N.; Iwai, M.; Sawa, H.; Fujino, H.; Taga, T.; Ota, S.; Shimada, M. Chemotherapy-Induced Unconjugated Hyperbilirubinemia Caused by a Mutation of the Bilirubin Uridine-50-diphosphate- glucuronosyltransferase Gene. J. Pediatr. Hematol. Oncol. 2001, 23 (1), 45-47. (Pubitemid 32124983)
22. Zucker, S. D.; Qin, X.; Rouster, S. D.; Yu, F.; Green, R. M.; Keshavan, P.; Feinberg, J.; Sherman, K. E. Mechanism of Indinavir-Induced Hyperbilirubinemia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (22), 12671-12676. (Pubitemid 33020004)
23. Jin, C.; Miners, J. O.; Lillywhite, K. J.; Mackenzie, P. I. Complementary Deoxyribo-Nucleic Acid Cloning and Expression of a Human Liver Uridine Diphosphate-Glucuronosyltransferase Glucuronidating Carboxylic Acid-Containing Drugs. J. Pharmacol. Exp. Ther. 1993, 264 (1), 475-479. (Pubitemid 23309239)
24. Bhasker, C. R.; McKinnon, W.; Stone, A.; Lo, A. C.; Kubota, T.; Ishizaki, T.; Miners, J. O. Genetic Polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at Amino Acid 268: Ethnic Diversity of Alleles and Potential Clinical Significance. Pharmacogenetics 2000, 10 (8), 679-685.
25. Lévesque, E.; Beaulieu, M.; Green, M. D.; Tephly, T. R.; Bélanger, A.; Hum, D. W. Isolation and Characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase Encoded by a Polymorphic Gene. Pharmacogenetics 1997, 7 (4), 317-325. (Pubitemid 27356932)
26. Oswald, S.; Haenisch, S.; Fricke, C.; Sudhop, T.; Remmler, C.; Giessmann, T.; Jedlitschky, G.; Adam, U.; Dazert, E.; Warzok, R.; Wacke, W.; Cascorbi, I.; Kroemer, H. K.; Weitschies, W.; von Bergmann, K.; Siegmund, W. Intestinal Expression of P-glycoprotein (ABCB1), Multidrug Resistance Associated Protein 2 (ABCC2), and Uridine Diphosphate-Glucuronosyltransferase 1A1 Predicts the Disposition and Modulates the Effects of the Cholesterol Absorption Inhibitor Ezetimibe in Humans. Clin. Pharmacol. Ther. 2006, 79 (3), 206-217.
27. Oswald, S.; Giessmann, T.; Luetjohann, D.; Wegner, D.; Rosskopf, D.; Weitschies, W.; Siegmund, W. Disposition and Sterol-Lowering Effect of Ezetimibe are Influenced by Single-Dose Coadministration of Rifampin, an Inhibitor of Multidrug Transport Proteins. Clin. Pharmacol. Ther. 2006, 80 (5), 477-485. (Pubitemid 44767877)
28. Oswald, S.; König, J.; Lütjohann, D.; Giessmann, T.; Kroemer, H. K.; Rimmbach, C.; Rosskopf, D.; Fromm, M. F.; Siegmund, W. Disposition of Ezetimibe is Influenced by Polymorphisms of the Hepatic Uptake Carrier OATP1B1. Pharmacogenet. Genomics. 2008, 18 (7), 559-568.